Currently out of the existing stock ratings of Laura Chico, 159 are a BUY (69.13%), 70 are a HOLD (30.43%), 1 are a SELL (0.43%).

Laura Chico

Work Performance Price Targets & Ratings Chart

Analyst Laura Chico works at WEDBUSH with a stock forecast success ratio of 47.14% fulfilled within 176.84 days on average.

Laura Chico’s has documented 474 price targets and ratings displayed on 38 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on STOK, Stoke Therapeutics at 26-Mar-2024.

Wall Street Analyst Laura Chico

Analyst best performing recommendations are on PRAX (PRAXIS PRECISION MEDICINES ).
The best stock recommendation documented was for DNLI (DENALI THERAPEUTICS) at 11/10/2020. The price target of $64 was fulfilled within 1 day with a profit of $4 (6.67%) receiving and performance score of 66.67.

Average potential price target upside

of $84.28 (52.75%) on PRAX (PRAXIS PRECISION MEDICINES ).
of $41.26 (35.62%) on KRTX (KARUNA THERAPEUTICS).
of $33.85 (29.73%) on ALXN (ALEXION PHARMACEUTICALS).

ACER Acer Therapeutics ALXN Alexion Pharmaceuticals APLS Apellis Pharmaceuticals APTX Aptinyx ARDX Ardelyx BHVN Biohaven Pharmaceutical Holding Co Ltd BIIB Biogen DNLI Denali Therapeutics KRTX Karuna Therapeutics NBIX Neurocrine Biosciences PRAX Praxis Precision Medicines RARE Ultragenyx RTRX Travere Therapeutics SAGE Sage Therapeutic TSHA Taysha Gene Therapies TVTX Travere Therapeutics VIE Viela Bio XENE Xenon Pharmaceuticals PRVL Prevail Therapeutics VYGR Voyager Therapeutics DSGN Design Therapeutics IMPL Impel Neuropharma VERA Vera Therapeutics STOK Stoke Therapeutics DOVA Dova Pharmaceuticals MLND Millendo Therapeutics PEPG PepGen Ltd VIGL Vigil Neuroscience VRTX Vertex Pharmaceuticals ATXS Astria Therapeutics PASG Passage Bio BMRN Biomarin Pharmaceutical EWTX Edgewise Therapeutics KDNY Chinook Therapeutics LBPH Longboard Pharmaceuticals PHVS Pharvaris BV RLYB Rallybio Corp VRDN Viridian Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Jonathan Aschoff (ROTH MKM)